Dexamethasone as Treatment in Cerebrovascular Disease. 1.
• Dexamethasone and a placebo were compared as treatment for 40 patients with intracerebral hemorrhage. Of 19 patients receiving dexamethasone, 17 (89.5%) died during their hospital admission. Of 21 patients receiving a placebo, 16 (76.2%) died. The mortality rate was 100% in 15 patients in the dexamethasone-treated group who were in coma or deep stupor on admission, and the mortality rate was 92% in 12 patients with similar levels of consciousness who received a placebo.
Several parameters of the neurological examination showed an improved quality of survival in the Decadron®-treated group, but this was found only at certain days in the study. No overall statistically significant difference was found between the two therapies.
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• A prospective study was formulated to evaluate the usefulness of treatment with dexamethasone (Decadron®) in patients with acute intracerebral hemorrhage. The rationale for the use of steroid preparations has been to lessen the damaging effect of cerebral edema, increased intracranial pressure and a disturbed blood-brain barrier, as well as to counteract the "stress" factor associated with acute cerebral infarction, hemorrhage or trauma. Sparacio et al. 1 reported beneficial effects from using methylprednisolone sodium succinate in acute craniocerebral trauma. Roberts 2 found adrenocortical steroids to be of great value as adjunctive therapy in the management of certain seriously ill patients with acute or subacute cerebrovascular accidents. Russek et al. 8 ' 4 reported that administration of cortisone produced dramatic clinical improvement when used as immediate therapy in the apoplectic stroke due to cerebral thrombosis or emboli, but it had no beneficial effect in three patients with cerebral hemorrhage.
Rubenstein 5 reported on the use of dexamethasone in six patients with intracerebral hemorrhage.
The dosage used was 4 mg intravenously and 4 mg intramuscularly at the onset of therapy, followed by 4 mg intramuscularly every six hours for 72 hours, for a total of 52 mg over a 72-hour period. Treatment was instituted within 24 hours of the attack. All six patients died within their hospital stay. The author stated that dexamethasone obviously did not alter the grave prognosis in patients with intracerebral hemorrhage.
Methods
Criteria to be met for inclusion into this study were as follows:
1. Clinical evidence of acute intracerebral hemorrhage due to either hypertension, hemorrhagic infarction or cerebral aneurysm. Trauma cases were excluded. Patients with subarachnoid hemorrhage, but with no neurological deficit, also were excluded. 5. Diagnosis made and treatment started within the first 48 hours following the onset of the catastrophic event for which the patient was admitted to the hospital.
Upon inclusion in the study each patient had a complete neurological examination which was recorded on a specially prepared evaluation sheet. An arbitrary point value was assigned to various functions so that a scoring system was available for patient comparison, with the maximum normal score being 68 points. The TELLEZ, BAUER variables measured were: level of consciousness (7 points); mental function, including orientation, attention, digit span, simple arithmetic, etc. (38 points); cranial nerve function (5 points); motor system function (11 points); reflex functions (3 points); and speech ability (4 points).
The levels of consciousness were defined as follows: deep coma (absent DTRs and pupillary reactions, corneal reflexes with no response to pain); coma (DTRs, pupillary reactions and corneal reflexes present but no response to pain); semicoma (nonspecific response to pain); deep stupor (purposeful response to pain); stupor (appropriate response to verbal stimuli); semi-stupor (lethargic, response slowed).
The arbitrary point value assigned to the neurological evaluation was as follows:
A. Level 
Mentation
A standardized testing method was used for each patient with the following point value: orientation and attention (15 points), digit span (10 points), mental arithmetic (9 points), and similarities and differences (4 points) (total, 38 points).
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The patients in this study were treated according to the following dosage schedule: (1) 3 cc intravenously stat (12 mg Decadron); (2) 1 cc intramuscularly every six hours for three days (48 mg Decadron); (3) 1 cc intramuscularly every eight hours for three days (36 mg Decadron); (4) 1 cc intramuscularly every 12 hours for two days (16 mg Decadron); and (5) 1 cc intramuscularly every 24 hours for two days (8 mg Decadron). Thus, a patient in the "treat" group received a total of 120 mg of Decadron over a ten-day period.
The patients were subsequently scored during the second, fourth, sixth, eighth, tenth and fourteenth day after admission to the study. The scoring table was more detailed in the area of level of consciousness and mentation, since it was expected that the most recognizable changes in condition in these critically ill patients would be in these spheres.
Lumbar punctures were done on the day of admission to the study and, when feasible, on the fifth, tenth and fifteenth days. Pressures, cell counts, glucose, proteins, Pandy's test and chlorides were recorded in most of the patients.
Arteriography was delayed until the end of the study whenever possible. If the patient's clinical condition warranted, emergency arteriography on selected vessels was performed. Effort was made to obtain autopsy examination on patients who expired in the hospital.
The first 17 patients were randomized into either "treat" or "control," and the subsequent 23 patients were treated by the double-blind method. As there was no statistical difference between these two patient groups, they were combined for analysis. The randomized control patients received appropriate supportive therapy. The randomized "treat" patients received appropriate supportive therapy plus a total of 120 mg of dexamethasone over a ten-day period according to the above schedule.
The double-blind group received a preparation from coded vials* which contained either Decadron (4 mg = 1 cc) or a placebo material. The code was broken after all patients were included in the series and the final clinical condition of all patients had been recorded.
Case Material
The 40 patients in this study were admitted to the Department of Neurology at Detroit General Hospital. The average age was 62.25 years. There were 15 females and 25 males, 26 Negroes and 14 Caucasians.
Thirty-eight patients (95%) were found to be hypertensive at the initial examination. Twenty-six (65%) had a history of hypertension. All patients were severely ill upon admission to the study.
Although all patients in this study were randomized into either the "treat" or the control group, with this small number of patients the average pretreatment score for the "treat" group (19 patients) was 13.05 points, and for the control group (21 patients) it was 17.86 points (table 1).
•Prepared by the Merck, Sharp and Dohme Co. It is noted that the pretreatment mentation value in the control group was 3.14 points (out of a possible 38 points) and in the "treat" group it was only 1.26 points out of a possible 38 points, indicating the severe disturbance in level of consciousness and therefore inability to perform mental function tests.
It would appear that the control group was not as severely ill as the "treat" group, although this is not supported by statistical significance. When examined further as to level of consciousness on admission, 15 of the 19 in the "treat" group were either in deep coma, semicomatose, comatose or in deep stupor, whereas only 12 of the 21 in the control group were in a similar state of consciousness (table 2) . No patient in either group had a normal level of consciousness. Whereas only four of the 19 in the "treat" group were in stupor or semi-stupor, nine of the 21 in the control group were in stupor or semi-stupor.
The clinical location of the lesions in the brain were as follows: right hemisphere, 12 patients (30%); left hemisphere, 17 patients (42.5%); and brain stem, 11 patients (27.5%). Location of the lesions was determined by clinical evidence, cerebral arteriography, and/or autopsy findings.
The final diagnoses in the control group was as follows: five patients with right intracerebral hemorrhage, five patients with left intracerebral hemorrhage, four patients with right cerebral hemorrhagic infarction, three patients with left cerebral hemorrhagic infarction, and four patients with brain stem hemorrhage.
The final diagnoses in the "treat" group were as follows: two patients with right intracerebral hemorrhage, six patients with left intracerebral hemorrhage, one patient with right cerebral hemorrhagic infarction, The admitting diagnosis was hemorrhagic infarction in four patients, whereas the final diagnosis was hemorrhagic infarction in 11 patients. In two instances this change in diagnosis was made because of autopsy findings, whereas in the other five cases this change in diagnosis was made because of the combination of relatively few RBCs in the spinal fluid and the fact that the patient survived.
Autopsies were performed on nine patients, four in the control group and five in the "treat" group. In the control group the autopsy confirmed the admitting diagnosis of intracerebral hemorrhage in two cases, changed the admitting diagnosis of intracerebral hemorrhage to brain stem hemorrhage in a third, and in the fourth case changed the diagnosis of intracerebral hemorrhage to that of hemorrhage into an old infarct. This same patient had had an arteriogram which demonstrated an anterior communicating artery aneurysm which, at autopsy, was shown to have not ruptured. In the "treat" group the autopsies confirmed the admitting diagnosis of intracerebral hemorrhage in all five cases.
Arteriography was performed in ten cases. In one case arteriography was performed prior to the fourteenth day and an aneurysm was found. This was the case mentioned above in which the autopsy showed that the aneurysm had not ruptured. In the other nine cases the patient had survived the fourteenth day, although three of these nine died while still in the hospital. None of these arteriograms demonstrated an aneurysm as a source of the intracerebral hemorrhage.
Two of an original 42 patients admitted to the study were excluded from analysis, leaving the 40 patients reported above. The first patient was a 70-yearold female with history of a stroke five years previously, who was brought to the hospital semicomatose and quadriparetic with 3,175 RBCs in her CSF. She showed little improvement with the randomized treatment (Decadron). Twenty-three days after admission an arteriogram showed a large left subdural hematoma. This was removed that same day but the patient died two days later. Autopsy confirmed the chronic subdural hematoma, the old right cerebral infarct with an 8 x 10 x 10 cm cavity, and evidence of increased intracranial pressure. She was excluded from analysis because accidentally she did not receive the Decadron during the first 24 hours after inclusion into the study and because the admitting diagnosis was in error.
The second patient excluded from the study was a 78-year-old known alcoholic with the sudden onset of left hemiparesis. There were 6,900 RBCs in the CSF. He became comatose within 24 hours and developed gastrointestinal bleeding, and the randomized treatment (Decadron) was discontinued. The patient died on the third hospital day. Autopsy showed infarction in the right cerebral hemisphere, as well as multiple acute bleeding ulcers of the gastrointestinal tract.
Results
There were 19 patients in the treated group and 21 in the control group. In the "treat" group, five improved and 14 had died at the end of 14 days. In the control group, five improved, one remained unchanged and 15 died at the end of 14 days. An additional four patients died prior to discharge or transfer from the hospital. Three were in the "treat" group and one in the control group. Thus, of 19 patients in the "treat" group, 17 (89.5%) died. Of the 21 patients in the control group, 16 (76.2%) died (table 2) .
Results were compiled according to the patient's level of consciousness when admitted to the study (table 3) . Of the 15 patients in the "treat" group who were in coma or in deep stupor, the mortality was 100%. Of the 12 patients in the control group who were in coma or in deep stupor, only one patient survived, for a mortality rate of 92%. Thus, there is no demonstrable lessening of mortality with the use of steroids, and this study only confirms the poor prognosis of patients with acute intracerebral hemorrhage. 6 Of the four patients in the "treat" group who were in stupor or semi-stuporous states, two died (50% ); of the nine patients in the control group in stupor or semi-stuporous states, five died (55%).
Again, there is no appreciable difference between the two groups.
The data from the protocols on all the patients were analyzed for any statistical difference between the "treat" and control groups regarding the clinical status at the second, fourth, sixth, eighth, tenth, and fourteenth day of survival. For level of consciousness, mean change from initial values for days 4, 6, 8, 10, and 14 gave statistically significantly better results with Decadron than with a placebo (table 4) .
Analysis of cranial nerve function showed no statistical difference between the "treat" and control patients, although the survivors in the "treat" group showed improvement (mean score) at each day, whereas the survivors in the control group showed a mean worsening (mean score) of cranial nerve function at each day.
Analysis of motor system function showed that the mean changes on day 6 were statistically significantly (p = <0.05) in favor of the survivors in the Decadron-treated group. For reflexes the adjusted change for the Decadron-treated group was statistically significantly better on day 6 (p = < 0.05) and day 14 (p = < 0.01) only. There was no Analysis also was made by assigning a "0" (0 = dead) to the scoring system for each parameter, and thereby combining the surviving and the dead. This was done for all the parameters described above and no statistically significant treatment differences were found. Analysis was made of the cumulative death rate in each group (table 7) . No statistically significant differences were found.
GASTROINTESTINAL BLEEDING
Cantu et al. 7 compared 200 patients who had undergone major intracranial surgery between the years 1962 and 1965 and who had received either dexamethasone or methylprednisolone in the immediate postoperative period for control of cerebral edema with 200 patients undergoing similar surgical procedures during the period 1955 to 1960, but who had not received steroids. Their study suggested that the risk of significant gastrointestinal hemorrhage in comatose patients following intracranial surgery is increased more than fourfold by the administration of high dosages (over 40 mg of methylprednisolone equivalent per day) of steroids in the postoperative period, and that the risk was the same for dexamethasone and methylprednisolone when administered in equivalent dosages.
In the study reported here there were four cases of gastrointestinal bleeding. Two occurred in the control group and two occurred in the Decadrontreated group. One patient with gastrointestinal bleeding in the treated group was excluded from analysis of active data but is included here as a complication of treatment. Table 8 records the finding of CSF pressure on admission to study as related to level of consciousness in the control and Decadron groups. One can hardly equate these pressures with cerebral edema, for the elevations are most likely due to the pressure of blood rather than edema. As expected, there were more elevated CSF pressures in the patients with coma than in those with stupor. This was present in both the control and the Decadron treatment patients prior to treatment.
CEREBROSPINAL FLUID PRESSURE
Observations on initial CSF pressure, subsequent CSF pressures and clinical status of the patients are detailed in table 9. There does not appear to be any difference in the subsequent CSF pressures between the control group and the treated group. The mortality rate is higher in those with increased CSF pressure in both the control and Decadron groups. 
